Lulizumab pegol clinical trials
Also written BMS-931699.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses lulizumab pegol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2022 | 1 |
Who runs them
Industry 3 · Other 2
Bristol-Myers Squibb (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lulizumab pegol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Treg Modulation With CD28 and IL-6 Receptor AntagonistsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT04066114Written as lulizumab pegolHow we know
- Selective CD28 Blockade in Renal Transplant RecipientsWithdrawnPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04903054Written as LulizumabHow we know
- Safety and Efficacy Study of a Biologic to Treat Systemic Lupus ErythematosusCompletedPhase 2Bristol-Myers SquibbNCT02265744Written as BMS-931699How we know
- Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's SyndromeTerminatedPhase 2Bristol-Myers SquibbNCT02843659Written as BMS-931699How we know
- Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in VialTerminatedPhase 1Bristol-Myers SquibbNCT03058822Written as BMS-931699How we know
Codes
What other systems call lulizumab pegol · ClinicalTrials.gg INT000394
- MeSH (NLM) C000604694lulizumab pegolOne source NLM
- UNII (FDA) LCT264LTYELULIZUMAB PEGOLConfirmed FDA, NLM, Wikidata
- Wikidata Q20706900lulizumab pegolConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C175727Lulizumab PegolOne source FDA
- DrugBank DB15441One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000604694 | lulizumab pegol | One source NLM |
| UNII (FDA) | LCT264LTYE | LULIZUMAB PEGOL | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q20706900 | lulizumab pegol | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C175727 | Lulizumab Pegol | One source FDA |
| DrugBank | DB15441 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.